slide1
Download
Skip this Video
Download Presentation
Avian Influenza H5N1 Reactive Antibodies

Loading in 2 Seconds...

play fullscreen
1 / 13

Avian Influenza H5N1 Reactive Antibodies - PowerPoint PPT Presentation


  • 135 Views
  • Uploaded on

Avian Influenza H5N1 Reactive Antibodies. BA 468x Technology Commercialization. The Team. Christopher Bush Computer Science, Entrepreneurship Kevin Irish Marketing, Multimedia, Entrepreneurship Kyle Winkler Construction Engineering Management, Entrepreneurship Dr. Manoj Pastey

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Avian Influenza H5N1 Reactive Antibodies' - andie


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Avian Influenza H5N1

Reactive Antibodies

BA 468x

Technology Commercialization

slide2

The Team

  • Christopher Bush
    • Computer Science, Entrepreneurship
  • Kevin Irish
    • Marketing, Multimedia, Entrepreneurship
  • Kyle Winkler
    • Construction Engineering Management, Entrepreneurship
  • Dr. Manoj Pastey
    • Inventor, Assistant Professor of Veterinary Medicine
  • Rob Schneider
    • Mentor, Self Employed
  • Sukanya Rengaswamy
    • Mentor, Hewlett-Packard
slide3

Definition & Status

What is Bird Flu?

  • Avian Influenza H5N1 “Bird Flu” & H7N2 virus
  • Found in wild ducks & geese (host)
    • Spread by droppings and nasal fluids
  • Highly pathogenic in poultry
  • High fatality rate

Current Status

  • Over 150 million birds destroyed
  • 291 human cases / 172 human deaths
  • Stage 3 of 6 WHO Global Pandemic Alert

Source: Foreign Agricultural Service/USDA Office of Global Analysis, April 2007http://www.who.int/csr/disease/avian_influenza/en/index.html

slide4

Spread of Avian Influenza

Bird Migration

H5N1 Outbreaks

slide5

Why License?

  • Global Distribution Channels
    • Since 2003, human cases of avian flu has been confirmed in 12 countries, and has been found in animals in 40 countries:
  • Speed to Market
    • 6 countries have reported avian influenza deaths in 2007.
  • Complimentary product
    • Diagnostic companies have a wide range of testing products.

Source: WHO

slide6

Our Technology

  • Antibodies to specifically detect the deadly H5N1 and H7N2 strains
  • Easy to incorporate into existing “on-site” tests
  • Used for chickens and humans
  • Results in 10 minutes
  • Easy to use
slide7

Why We Win

Current Lab Test

Positive

Current Field Test

Positive

AvianLabsAntibodies

slide8

Technology Timeline

2006

2007

2008

2009

Proof of Concept

Proof of Concept

Prototyping

Prototyping

Product Intro.

Product Intro.

Manf. Ramp

Manf. Ramp

USDA Research Grant Awarded

Initial R&D – 8 mo

Research Potential Licensees – 2 mo

Completion of R&D – 6 mo

Finalize Patent Claims – 6 mo

Licensee Internal Review – 2 mo

Licensing Negotiations – 4 mo

Initial Marketing/Sales – 6 mo

Manufacturing ramp up – 8 mo

slide9

Testing Market

Migratory

Wild Bird

Testing

Poultry

Testing

Governments/

Regulatory

Agencies

Governments/

Regulatory

Agencies

Farmers

Target Market

  • Governments
    • Monitor Migratory Wild Birds
    • Prevent Spread into Country
    • Protect its citizens
    • Prevent Global Pandemic
    • Regulate Poultry Industry
  • Farmers
    • Target Market
    • Prevent Large Scale Economic Loss
    • Provides “Insurance” Policy
slide10

Sales Forecast

Assumptions:

    • 6 Billion Chickens (Asia)
    • 0.5% - 1.0% tested monthly
  • Source: Cheok Soh Hui, ICIS Chemical Business, 2006

In millions

excluding “price per kit”

slide11

Revenue Forecast

All $ in millions

Excluding “price per kit”

slide12

Current Issues/Future Potential

Issues

Solutions

  • Virus Mutations
  • Technology IP
  • Lab Predictions
    • Escape Mutants
  • Currently Strengthening Claims

Future Markets & Potential

  • Customs (Border Crossings)
  • All Species
  • Human Antivirals & Vaccines
slide13

Contact Information

Thank you for allowing us to present our technology.

Questions or Comments?

ad